The core problem the researchers set out to solve is deceptively simple to state. Wound healing in diabetes is a complex, slow and frequently derailed biological process, often complicated by infection and poor blood supply. Clinical assessment currently relies on visual examination and surface measurement, methods the authors describe as strongly subjective and incapable of evaluating what lies beneath the wound bed. A wound may look dry and closed while the microvascular network beneath it remains dysfunctional and fragile, a mismatch that contributes to the high rate of ulcer recurrence. What is needed, the team argued, is a way to quantify the repair process itself: how blood flows through the skin, how new vessels sprout and mature, and how the internal architecture of the wound remodels over time.

No single imaging modality can capture all of that at once, which is precisely why the researchers combined three. The first is laser speckle contrast imaging, or LSCI, a technique that shines coherent laser light across the wound surface and reads the interference patterns, or speckles, produced by moving red blood cells. Because the blurring of the speckle pattern is directly related to the speed of blood flow, LSCI can generate real-time, full-field maps of cutaneous blood perfusion without any contrast agent, any contact and any ionizing radiation. It is essentially a live weather map of circulation at the wound surface, refreshed many times per second.

The second technique reaches deeper into the near-infrared spectrum. Second near-infrared region imaging, known as NIR-II, operates at wavelengths roughly between 1,000 and 1,700 nanometers, where tissue scatters far less light than in the visible range. The result is dramatically improved penetration depth and spatial resolution, allowing the team to trace the spatial and temporal evolution of vascular networks as they regrew across the healing wounds. Whereas LSCI reports on how fast blood moves, NIR-II delineates the plumbing itself, the architecture of the vessels carrying that blood, resolved in three dimensions over days and weeks.

The third modality, optical coherence tomography angiography, or OCTA, borrows the depth-resolving power of OCT and applies it to moving blood cells. By detecting flow-induced changes in repeated cross-sectional scans, OCTA reconstructs high-resolution maps of microvessels without injecting any dye, while simultaneously characterizing the internal microarchitecture of the wound. Together the three techniques span a striking range of scales: LSCI for dynamic whole-surface perfusion, NIR-II for vascular network structure over time, and OCTA for depth-resolved microvascular and tissue detail. The researchers describe the resulting dataset as a uniquely comprehensive record of the microvascular repair process, one that no individual modality could deliver on its own.

To put the platform to the test, the team carried out longitudinal imaging of full-thickness skin wounds in both normal mice and db/db mice, a widely used model of type 2 diabetes in which wounds heal slowly and incompletely, mirroring the clinical situation. All animal work was conducted between August 2024 and March 2025 under protocols approved by the Ethics Committee of the Second Hospital of Shanxi Medical University, in accordance with National Institutes of Health guidelines, with anesthesia, analgesia and standard-compliant postoperative care to minimize suffering. The multimodal setup allowed the same wounds to be tracked continuously through the entire healing trajectory, a demanding experimental design that required synchronizing three optical systems around a single wound site over many sessions.

The results demonstrated that each modality pulled its weight, and that their combination produced information neither could supply alone. LSCI captured real-time dynamic changes in cutaneous blood perfusion, revealing how flow returned, fluctuated and redistributed across the wound surface as healing advanced. NIR-II imaging traced the growth and remodeling of vascular networks in space and time, documenting the emergence of new vessel structures that later consolidated. OCTA, meanwhile, peered inside the wound to characterize microarchitecture and microvascular patterns at high resolution, exposing differences between normally healing wounds and the impaired regeneration seen in the diabetic animals. The platform thereby enabled both qualitative and quantitative assessment of wound repair capacity, with the authors describing the resolution and completeness of the data as unprecedented.

Beyond simply watching wounds close, the study had a therapeutic ambition. The team used the platform to quantitatively evaluate zinc-ion-based treatment strategies aimed at promoting the reconstruction of microcirculation in diabetic wounds. Zinc has long interested wound researchers for its roles in enzymatic function, immune defense and angiogenesis, but demonstrating that a pro-angiogenic therapy is actually rebuilding functional vessels, rather than merely shrinking a wound, requires exactly the kind of vascular-level measurement the new platform provides. By combining perfusion data from LSCI, structural vascular data from NIR-II and depth-resolved microvascular data from OCTA, the researchers could assess treatment effects across multiple physiological dimensions simultaneously, rather than inferring efficacy from wound area alone.

The implications for clinical practice could be significant. Diabetic wound care currently suffers from a measurement gap: decisions about debridement, dressings, revascularization procedures and amputation are guided largely by surface appearance, photographs and manual measurements, supplemented in some centers by transcutaneous oxygen testing or Doppler ultrasound. Laser Doppler flowmetry, an older optical perfusion technique, measures flow only at single points, while indocyanine green angiography requires an injected dye and offers limited depth information. The platform presented by the Shanxi team addresses these shortcomings by fusing agent-free, contact-free measurements of flow, vessel architecture and tissue structure into a single longitudinal record. The authors argue that the approach demonstrates promising feasibility for assessing novel pro-angiogenic treatments and may eventually help guide clinical wound management, although translation from mice to patients will require further validation, including work on appropriate imaging windows for human tissue and the workflow demands of busy clinics.

The study also fits into a broader movement in biomedical optics toward multimodal, quantitative imaging of disease processes. Techniques such as polarization-sensitive OCT, magnetic resonance angiography and advanced fluorescence imaging each contribute pieces of the wound-healing picture, but their integration into a practical bedside workflow remains an open challenge. What the Shanxi team has shown is that three optical methods with overlapping but distinct strengths can be orchestrated to produce a coherent, quantifiable narrative of tissue repair, from the first surge of perfusion at the wound margin to the maturation of a new capillary network beneath a closing epithelium. If that narrative can eventually be read in a human clinic as reliably as it now can in a mouse model, the humble ruler may finally give way to a far more revealing instrument, one that sees not just whether a wound is closing but whether the vessels underneath it are truly built to last.

Subject of Research: Multimodal noninvasive optical imaging of microvascular repair in diabetic wound healing

Article Title: Noninvasive assessment of the repair process in diabetic wound healing using multimodal imaging techniques

Article References: Li, Y., Zhang, H., Ren, Y., Wang, H., Cao, G., Fan, K., Lu, C., Zhang, Y., Han, J., & Dong, H. (2026). Noninvasive assessment of the repair process in diabetic wound healing using multimodal imaging techniques. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02811-4

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02811-4

Keywords: diabetic wound healing, laser speckle contrast imaging, NIR-II imaging, OCTA, angiogenesis, blood perfusion, microcirculation, noninvasive imaging, db/db mice, wound assessment, biomedical optics, zinc therapy

FBP1 catalyzes the irreversible hydrolysis of fructose-1,6-bisphosphate into fructose-6-phosphate, making it the rate-limiting enzyme of gluconeogenesis. In recent years it has attracted attention in oncology, where it suppresses glycolysis by restraining the HIF-1α pathway and acts as a protein phosphatase that dephosphorylates targets such as histone H3 and telomerase reverse transcriptase. But its role in diabetic wound healing had never been systematically characterized. To close that gap, the team built an in vitro model of the diabetic wound microenvironment using HaCaT keratinocytes, the workhorse cells of epidermal renewal, exposed to methylglyoxal. Methylglyoxal is a highly reactive α-dicarbonyl metabolite that accumulates in hyperglycemic tissue and drives the formation of irreversible advanced glycation end-products, fueling collagen cross-linking and microvascular damage. Dose-response experiments identified 400 micromolar methylglyoxal as a concentration that significantly suppressed keratinocyte proliferation, impaired colony formation, and crippled cell migration in scratch and transwell assays, faithfully mimicking the cellular defects seen in chronic diabetic wounds.

With the model established, the researchers turned to transcriptome-wide RNA sequencing to find the molecular drivers of dysfunction. The analysis revealed 1,375 upregulated and 724 downregulated genes in methylglyoxal-treated cells, with gene ontology annotations pointing to defects in cytoplasmic and plasma membrane components and KEGG enrichment implicating type 1 diabetes, diabetic complications, and growth regulation. Among the differentially expressed genes, one stood out: FBP1 was significantly upregulated by methylglyoxal exposure. Functional validation quickly established the enzyme as a negative regulator of repair. Keratinocytes engineered to overexpress FBP1 using lentiviral vectors showed markedly reduced proliferation and migration, while cells treated with FBP1-specific small interfering RNA proliferated and migrated more vigorously. MTT and colony formation assays quantified the effect, confirming at the statistical level of P less than 0.01 that FBP1 is a significant inhibitor of the two cellular behaviors on which wound closure most depends.

Having identified the target, the team went hunting for an inhibitor. Using the crystal structure of human FBP1 as a template, they virtually screened a library of 2,100 natural products, first filtering candidates through Lipinski’s Rule of Five and then docking them into the enzyme’s fructose-6-phosphate binding pocket with the LibDock and CDOCKER algorithms in Discovery Studio. From the top-ranked hits, in vitro enzymatic testing singled out asiatic acid, a pentacyclic triterpenoid from Centella asiatica long used in traditional wound care. Molecular docking showed asiatic acid nesting snugly in the catalytic pocket, forming hydrogen bonds with ARG25, MET30, and LYS112 and hydrophobic contacts with ALA24, ARG140, and MET177, at a docking energy of −7.15 kcal/mol. Its measured inhibitory potency, an IC50 of 2.50 micromolar, actually exceeded that of adenosine monophosphate, the enzyme’s endogenous inhibitor. A cellular thermal shift assay, in which treated cells are heated across a temperature gradient, confirmed that asiatic acid binds FBP1 directly inside living cells, stabilizing the protein between 48 and 62 degrees Celsius.

Mechanistically, asiatic acid’s benefits flowed through a well-defined signaling cascade. Western blotting showed that methylglyoxal suppressed phosphorylation of AKT and mTOR along with downstream HIF-1α and uPAR, proteins that together drive keratinocyte proliferation and migration. Treatment with 20 micromolar asiatic acid restored the p-AKT/AKT and p-mTOR/mTOR ratios and lifted HIF-1α levels 1.7-fold and uPAR levels 2.3-fold. Importantly, the compound left total FBP1 expression unchanged, demonstrating that it works through direct enzymatic inhibition rather than transcriptional repression. Phalloidin staining added a striking visual dimension: methylglyoxal and FBP1 overexpression fragmented the actin cytoskeleton, and asiatic acid partially restored filamentous actin organization, linking FBP1 inhibition to the cytoskeletal mechanics of cell migration.

But asiatic acid has a practical flaw: its high polarity limits skin permeability. The chemists responded with rational design. They acetylated hydroxyl groups on the molecule’s A-ring to balance solubility and membrane permeability, then conjugated the scaffold to three different hydrogen sulfide donors. Hydrogen sulfide, the most recently recognized gasotransmitter alongside nitric oxide and carbon monoxide, has well-documented pro-healing credentials, from AMPK-mediated angiogenesis to preservation of mitochondrial membrane potential in stressed keratinocytes. Among the resulting conjugates, one derivative, AA4, outperformed the rest by a wide margin, enhancing proliferation of methylglyoxal-injured keratinocytes more than tenfold compared with the parent compound at equivalent concentrations.

AA4 proved to be more than a simple inhibitor. In vitro enzymatic assays confirmed that it retained asiatic acid’s FBP1-blocking power, with an IC50 of 2.38 micromolar. Yet western blots revealed that AA4 also lowered FBP1 protein levels, and the mechanism proved to be chemistry of an unusual kind. When the team scavenged hydrogen sulfide using oxidized glutathione, FBP1 expression rebounded, and the reducing agent dithiothreitol reversed AA4’s effect, lifting FBP1 levels nearly fivefold. Together these experiments indicate that AA4’s hydrogen sulfide release promotes FBP1 protein degradation through persulfidation, a sulfur-based post-translational modification that marks the enzyme for breakdown. The result is a dual attack: asiatic acid directly jams the enzyme’s catalytic activity while the released gas erases the protein itself. Rescue experiments underscored the significance, with AA4 restoring 82 percent of methylglyoxal-impaired migration and 3.3-fold higher proliferation in FBP1-overexpressing cells.

The derivative’s most important gift to wounded tissue, however, may be keeping keratinocytes alive. RNA sequencing of AA4-treated cells showed 748 upregulated and 1,422 downregulated genes relative to injured controls, with strong enrichment of apoptotic pathways and a signature of increased Bcl-2 and decreased FBP1. Flow cytometry, Hoechst nuclear staining, and TUNEL assays confirmed that AA4 dramatically reduced apoptosis in both methylglyoxal-challenged and FBP1-overexpressing cells. At the protein level, injury models showed a 5.8-fold increase in the pro-apoptotic Bax/Bcl-2 ratio along with elevated cleaved Caspase-3 and PARP; AA4 treatment raised Bcl-2 3.5-fold, cut Bax by 69.3 percent, and reduced cleaved Caspase-3 and PARP by 64.4 percent. When hydrogen sulfide was scavenged, this protection vanished, and in cells where FBP1 had been knocked down, AA4 offered no further benefit, proving its anti-apoptotic effect depends entirely on the presence of its target.

The decisive test came in living animals. The team induced diabetes in mice with streptozotocin, created full-thickness dorsal wounds, and applied AA4 in a Pluronic F-127 hydrogel that released more than 80 percent of its payload within 12 hours. The results were striking. By day seven, wounds treated with 1 milligram per milliliter AA4 had closed by 90.7 percent, compared with just 50 percent in untreated diabetic controls, and the 3 milligram per milliliter formulation achieved 95.5 percent closure, outperforming both native asiatic acid and adenosine monophosphate. Histology revealed thicker stratum corneum, enhanced epidermal regeneration, and denser collagen deposition, while immunohistochemistry confirmed suppression of FBP1 in the healing tissue. The treatment also calmed the inflammatory storm that stalls diabetic wounds: mRNA levels of IL-1β, IL-6, IL-8, and TNF-α, all elevated in diabetic wounds, fell after AA4 application, and macrophage markers shifted from the pro-inflammatory M1 phenotype, marked by CD86, toward the pro-healing M2 phenotype, marked by CD206. Using the methylene blue method, the researchers verified that AA4 released hydrogen sulfide sustainably, restoring wound tissue gas levels to 45.9 micromolar and reversing the hydrogen sulfide deficiency characteristic of diabetes.

The study, whose authors say the work was conducted with ethical approval and without competing interests, is notable both for the target it unveils and for the strategy it embodies. By pairing unbiased transcriptomics with structure-guided drug design, the researchers moved from a differentially expressed gene to a chemically optimized, dual-mechanism therapeutic in a single program. FBP1, long studied in the contexts of gluconeogenesis and tumor metabolism, now emerges as a druggable node in regenerative medicine, while AA4 demonstrates how conjugating a natural product with a gasotransmitter donor can overcome pharmacological limitations. The specific persulfidation sites on FBP1 and the degradation pathways involved remain to be mapped, and clinical translation will require further development. But for patients whose wounds linger for months or years, the prospect that a derivative of a traditional medicinal plant, supercharged with a signaling gas, could more than double healing rates within a week offers a genuinely new direction, one in which precision target discovery and rational molecular engineering finally converge on one of diabetes’ most stubborn complications.

The material at the heart of the study is a thermosensitive hydrogel loaded with two types of functional nanomaterials: flower-shaped nanoparticles of molybdenum disulfide (MoS2) and zinc oxide (ZnO) nanoparticles, all embedded within a matrix formed from tannic acid and glycerol monostearate derivatives. The researchers designated this composite MoS2–ZnO@TM/TA. Each component plays a distinct role. The MoS2 nanoflowers are potent photothermal agents: when illuminated with near-infrared (NIR) light, they absorb the radiation and convert it into localized heat with high efficiency. ZnO nanoparticles contribute intrinsic antibacterial activity, partly through the release of zinc ions, which disrupt bacterial membranes and metabolism, and partly through their capacity to modulate reactive oxygen species. Tannic acid, a plant-derived polyphenol, acts as a natural crosslinker and antioxidant, while the lipid-derived monoglyceride component confers the temperature-sensitive gelation behavior that makes the material injectable.

The physical characterization of the hydrogel reveals a suite of properties that are unusually well matched to the demands of wound treatment. At room temperature in phosphate-buffered saline, the material swells to 93 percent of its capacity, allowing it to absorb wound exudate without dissolving. More striking is its shear-thinning rheology: when the shear rate applied to the material increases from 0.1 to 100 per second, its viscosity plummets from 1423 millipascal-seconds down to just 26. In practical terms, this means the hydrogel is thick and stable when sitting still, but flows readily when pushed through a syringe needle. Once deposited into the irregular geometry of a wound bed, it resettles into a soft, conformal gel that maintains intimate contact with the tissue. This injectability is a significant advantage over preformed dressings, which often fail to fill deep or unevenly shaped lesions.

The hydrogel’s responsiveness does not stop at shear. The material also exhibits temperature- and pH-sensitive behavior, which is critical because diabetic wounds present an abnormal microenvironment: they tend to be warmer than healthy skin, more acidic due to accumulated lactic acid and bacterial metabolism, and enriched in degradative enzymes. By tuning the gel matrix so that its structure and release profiles respond to these cues, the researchers built a degree of “intelligence” into the dressing. The hydrogel remains stable under normal conditions but becomes more active precisely where the pathological conditions of a chronic wound exist, delivering its therapeutic payloads where they are needed most and limiting off-target effects on healthy surrounding skin.

The photothermal performance of the composite is central to its antibacterial power. Under near-infrared light at an irradiance of 0.8 watts per square centimeter, the hydrogel raises the local temperature to 53 degrees Celsius within just eight minutes. This level of heating is lethal to bacteria but, when carefully controlled, tolerable for surrounding tissue over short exposures—a therapeutic window that photothermal therapy strategies have exploited in recent years. The heat disrupts bacterial membranes, denatures essential proteins, and, crucially, attacks the extracellular polymeric substance matrix that glues biofilms together. Biofilms are notoriously resistant to conventional antibiotics, with embedded cells often tolerating drug concentrations hundreds to thousands of times higher than their free-swimming counterparts. Physical heat penetrates this protective matrix in a way that molecules often cannot.

The antimicrobial results reported in the study are dramatic. The photothermal hydrogel achieved a 98 percent kill rate against both multidrug-resistant Escherichia coli and multidrug-resistant Staphylococcus aureus, two of the most clinically worrisome wound pathogens. Against established biofilms, the material cleared more than 80 percent of the biomass. These figures matter because multidrug-resistant infections are rising globally, and the World Health Organization has identified antimicrobial resistance as one of the top threats to public health. A dressing that does not rely on antibiotics at all, but instead on physical and nanoscale mechanisms that bacteria have difficulty resisting, offers a valuable alternative in the arms race against resistant organisms.

Mechanistically, the system operates through what the authors describe as a synergistic triad of “photothermal sterilization, inflammatory repair, and microenvironment regulation.” The MoS2 nanoflowers generate the heat that kills bacteria and breaks up biofilms. The ZnO component provides ongoing ion-based antimicrobial pressure between light treatments and contributes zinc ions that support tissue repair processes. The tannic acid within the network scavenges excess reactive oxygen species, which are known to accumulate in chronic wounds and perpetuate tissue damage, while also modulating the inflammatory response that otherwise stalls healing in the chronic phase. Together, these actions shift the wound from a destructive, bacteria-dominated state toward one permissive for cell migration, angiogenesis, and new tissue formation.

The in vivo evidence comes from experiments in diabetic mouse models, which are the standard preclinical platform for wound-healing studies. The results were striking. By day 9 after hydrogel treatment, new skin tissue had already emerged over the treated wounds—a stage at which untreated lesions typically remain open and inflamed. By day 21, the wounds treated with the hydrogel showed a healing rate approximately 50 percent higher than that of the blank control group. Histological assessments accompanying the study indicated improved re-epithelialization and tissue organization in the treated animals. The researchers also reported that the material is biocompatible, an essential prerequisite for any clinical translation, with no significant toxicity observed toward host cells in the tested conditions.

The broader significance of this work lies in how it reframes the problem of diabetic wound care. Traditional dressings are largely passive: they keep the wound moist and provide a physical barrier, but they do little to actively reshape the hostile biology of a chronic lesion. Antibiotic-laden dressings face the twin problems of resistance and off-target disruption of beneficial microbes. The MoS2–ZnO@TM/TA hydrogel represents a third path—an active, multifunctional platform that senses and responds to the wound environment, physically destroys biofilms with light-triggered heat, and simultaneously calms the inflammatory storm that keeps diabetic wounds frozen in a non-healing state. The ability to inject the material also opens the door to minimally invasive application, potentially allowing clinicians to treat deep or tunneling wounds that conventional dressings cannot reach.

Challenges remain before such a system could reach patients. The study relies on near-infrared light delivered from an external source, which raises questions about penetration depth in thick or deeply located tissues, and the long-term fate of the inorganic nanoparticles within the body will require careful toxicological scrutiny. Scaling up the synthesis of well-characterized MoS2 nanoflowers and ensuring batch-to-batch consistency are further hurdles. Nevertheless, the convergence of injectability, on-demand photothermal activation, antibiotic-free bacterial killing, and microenvironment-responsive behavior in a single material marks a substantial advance. For the millions of people worldwide at risk of diabetic foot ulcers—lesions that too often end in amputation—this multifunctional hydrogel offers a glimpse of a future in which wound dressings do far more than cover an injury: they actively fight it.

The study was conducted by internists Muhammet Ateş and Barış Karagün of the Department of Internal Medicine at Adana City Training and Research Hospital in Adana, Türkiye. Working from the hospital’s anonymized records, the pair assembled a retrospective cohort of 220 adults admitted for treatment of an infected diabetic foot wound. For every patient, they recorded the admission serum concentration of 25-hydroxyvitamin D, the stable storage form of vitamin D that clinical laboratories use as the standard yardstick of vitamin status. Deficiency was defined, in line with conventional thresholds, as a level below 20 nanograms per milliliter. The prevalence result was arresting: 109 of the 220 patients, or 49.5 percent, were vitamin D deficient on the day of admission. In other words, roughly one in every two patients arriving with a diabetic foot infection was already running on empty reserves of a hormone-like nutrient that immune cells depend on.

Diabetic foot infection is among the most feared complications of diabetes, and its biology explains why. Chronically high blood sugar damages peripheral nerves, so patients lose the protective pain sensation that would normally alert them to a blister or small ulcer early. Meanwhile, diabetes narrows and stiffens the arteries of the leg, starving the wound of the oxygen and immune cells that healing requires. Hyperglycemia also handicaps the defenses directly: neutrophils, the frontline white blood cells that engulf bacteria, move, adhere and kill less efficiently when glucose runs high. The result can be an ulcer that progresses from a superficial sore to a deep, bone-invading infection. To standardize comparisons, the researchers graded every infection using the criteria of the International Working Group on the Diabetic Foot and the Infectious Diseases Society of America, which classify infections as mild, moderate or severe according to depth, extent and the presence of a systemic inflammatory response. In this cohort, 103 patients (46.8 percent) had mild infections, 66 (30.0 percent) moderate and 51 (23.2 percent) severe.

The first biomarker, vitamin D, is less a vitamin than a secosteroid hormone. The 25-hydroxyvitamin D measured in the study is produced in the liver and circulates for weeks as the body’s reservoir; the kidneys and, crucially, immune cells themselves convert it into the active hormone 1,25-dihydroxyvitamin D. Immune cells are not bystanders in this system. Macrophages, dendritic cells and lymphocytes carry vitamin D receptors, and when activated vitamin D binds to them, it switches on genes encoding antimicrobial peptides such as cathelicidin—natural antibiotics that disrupt bacterial membranes—while tempering the release of inflammatory cytokines. Deficiency is especially common in type 2 diabetes: excess adipose tissue sequesters the fat-soluble vitamin, chronic hyperglycemia interferes with its activation, and diabetic kidney impairment can blunt the final activation step. A level below 20 ng/mL, the threshold used here, is conventionally read as frank deficiency—a state in which the immune system may be operating without one of its chemical co-pilots.

The second biomarker family is even cheaper: four inflammation indices computed arithmetically from the standard complete blood count that virtually every admitted patient already receives. The neutrophil-to-lymphocyte ratio divides the absolute neutrophil count by the absolute lymphocyte count, capturing the classic signature of acute physiological stress—neutrophils surge into the circulation under cortisol, catecholamines and interleukin-6, while lymphocytes fall. The platelet-to-lymphocyte ratio adds platelets, which climb as part of the inflammatory response. The systemic immune-inflammation index multiplies platelet count by neutrophil count and divides by lymphocyte count, producing a composite gauge of the combined inflammatory armament. The systemic inflammation response index multiplies neutrophils by monocytes—the cells that sustain and orchestrate chronic inflammation—divided by lymphocytes. Because all four indices can be derived from numbers already printed on any admission blood panel, they cost nothing and can be calculated within minutes of arrival, turning routine laboratory output into an immediate readout of the body’s inflammatory temperature.

When the researchers split the cohort by vitamin D status, the deficient group looked sicker across the board. Body mass index averaged 32.1 versus 29.9 kg/m² in the replete group, and long-term glucose control, gauged by glycated hemoglobin (HbA1c), was substantially worse at 9.1 versus 8.3 percent, with both comparisons significant at p < 0.001. The inflammatory indices told the same story: median NLR was 5.7 (interquartile range 4.3–7.3) in deficient patients versus 3.6 (3.0–5.0) in those with adequate vitamin D, while the systemic immune-inflammation index registered 1774.0 (1282.0–2499.0) versus 1042.0 (812.5–1450.0). The most consequential difference was time: deficient patients spent a median of 14.0 days in hospital (interquartile range 12.0–17.0), compared with 10.0 days (8.0–12.0) for the replete. Severe infection was more than three and a half times as common in the deficient group, affecting 36.7 percent versus 9.9 percent. On every measure captured at the bedside, low vitamin D flagged a patient in deeper trouble.

Equally striking was the graded pattern across infection severity. Moving from mild to moderate to severe disease, mean 25-hydroxyvitamin D stepped down in lockstep, from 22.1 ± 4.8 ng/mL in mild cases to 17.1 ± 4.2 ng/mL in severe ones, while median NLR climbed from 3.3 (2.7–4.0) to 8.2 (6.9–9.1), both trends robust at p < 0.001. In epidemiology, such a dose-response gradient is one of the classic signals that an association may be more than statistical noise: the deeper the infection, the lower the vitamin and the hotter the inflammation. Alongside these group comparisons, the team ran correlation analyses, logistic regression, linear regression and receiver operating characteristic analyses, a statistical battery designed to test whether the raw associations would survive once other clinical variables entered the equation.

The decisive results came from the multivariable models. In adjusted logistic regression, two variables emerged as independently associated with severe infection: the admission NLR, with an adjusted odds ratio of 3.06 per unit increase (95 percent confidence interval 2.09–4.48, p < 0.001), and serum albumin, with an adjusted odds ratio of 0.10 per unit increase (95 percent confidence interval 0.01–0.76, p = 0.026). Albumin, the liver’s most abundant export protein, is a negative acute-phase reactant: its concentration falls as inflammation ramps up, as nutrition falters and as damaged vessels leak protein into tissue. A low albumin therefore works as a composite alarm for catabolism, malnutrition and systemic illness—precisely the terrain on which severe diabetic foot infections flourish. Notably, vitamin D deficiency itself dropped out as an independent predictor of severity once other variables were accounted for. For length of stay, however, deficiency held its ground: in adjusted linear regression, vitamin D deficiency carried a coefficient of 0.192 (95 percent confidence interval 0.112–0.273, p < 0.001) and NLR a coefficient of 0.052 (95 percent confidence interval 0.036–0.068, p < 0.001), meaning both remained associated with longer admissions after correction.

The authors are explicit that these are associations, not verdicts on causation. The study was retrospective and single-center, built on anonymized hospital records from one institution; the protocol was approved by the hospital’s ethics committee in March 2026, with informed consent waived under the anonymized design. Reverse causality is a live possibility: systemic infection and inflammation can themselves disturb vitamin D metabolism and suppress its circulating levels, so a low 25-hydroxyvitamin D reading may partly be a consequence of severe illness rather than a contributor to it. Deficiency could also simply be a proxy for the metabolic storm that surrounds diabetic foot disease—obesity, poor long-term glycemic control, malnutrition and reduced mobility all deplete vitamin D while independently worsening outcomes. Ateş and Karagün accordingly frame their results as hypothesis-generating. Their conclusion draws a careful line: elevated admission NLR and hypoalbuminemia may warrant closer assessment for severe infection, while low 25-hydroxyvitamin D should be interpreted as a marker of overall vulnerability rather than a target that correction alone is guaranteed to fix. No vitamin D supplementation was tested.

Even so, the practical signal is difficult to ignore. The two instruments that carried the strongest associations—a white-cell ratio and a vitamin level—are among the cheapest tests in existence, orderable in any emergency department in the world. If prospective studies replicate these findings, an admission checklist for diabetic foot patients could take shape: calculate the NLR, check the albumin, note the vitamin D. Patients with a high ratio and low protein might be routed toward closer monitoring, earlier imaging for deep involvement and more aggressive initial antimicrobial therapy, while deficient patients could simply be expected to stay longer and be planned for accordingly. The study also feeds a broader scientific current: the search for free, computable inflammation gauges that transform routine blood counts into risk stratification. With diabetes prevalence climbing worldwide and foot disease claiming a heavy share of diabetes-related hospital days, a zero-cost warning system read off numbers clinicians already possess is exactly the kind of simple idea with far reach. Whether restoring vitamin D can shorten those fourteen-day stays is a question only intervention trials can answer.

The core of this innovation lies in the strategic targeting of Smad7, an intracellular protein that plays a pivotal role in regulating the transforming growth factor-beta (TGF-β) signaling pathway. TGF-β is critically involved in wound healing; however, its dysregulation in diabetic patients often results in impaired tissue regeneration. By enhancing the expression of Smad7 specifically within the epidermal layers and the underlying stroma, the new biologic counteracts the pathological overactivation of TGF-β signaling that hampers healing processes. This fine-tuned intervention provides a dual advantage: suppressing deleterious fibrotic responses while fostering a conducive environment for cell proliferation and differentiation necessary for tissue repair.

Delving deeper into the mechanistic aspects, the research team engineered a sophisticated delivery system ensuring precision targeting of Smad7 to key cellular populations in the skin. Utilizing viral vectors adapted for high specificity and safety, they achieved localized overexpression of Smad7 in both keratinocytes of the epidermis and fibroblasts within the dermal stroma. This meticulous design addresses a longstanding hurdle in biologic therapies—the ability to modify intracellular signaling pathways in specific cell types without eliciting off-target effects or systemic toxicity.

Experimental validation was conducted using streptozotocin-induced diabetic mice and a porcine model that closely mimics human skin physiology and wound healing dynamics. In both species, treatment with the Smad7-based biologic resulted in markedly accelerated wound closure rates, improved re-epithelialization, and reduced fibrotic scar formation. Histological analyses revealed increased keratinocyte migration and proliferation, alongside enhanced angiogenesis in the wound bed, highlighting the multi-faceted impact of Smad7 modulation on the coordinated phases of healing—hemostasis, inflammation, proliferation, and remodeling.

Additionally, the researchers performed transcriptomic profiling of treated versus control wounds, uncovering significant shifts in the expression of genes related to extracellular matrix remodeling, inflammatory cytokine suppression, and growth factor signaling. These molecular changes underpin the observed phenotypic improvements and suggest that Smad7-driven therapeutic approaches may recalibrate the wound microenvironment from a chronic, inflammatory state to one favoring regeneration and homeostasis. This reprogramming of cellular behavior represents a novel paradigm in treating non-healing wounds, particularly in diabetic patients where persistent inflammation and impaired cellular responses are principal pathological factors.

The implications of this research extend beyond acute wound healing. Chronic ulcers, especially those associated with vascular complications in diabetes, pose a significant burden on patients and health systems worldwide. Current remedies, including debridement, topical agents, and advanced dressings, provide limited efficacy and fail to address the underlying molecular dysfunctions. The Smad7 biologic introduces a fundamentally new therapeutic avenue by targeting intracellular signaling cascades, potentially offering a durable solution that enhances endogenous repair mechanisms rather than merely managing symptoms.

Importantly, the deployment of this therapy in a large animal model like the pig is a critical step toward clinical translation. Porcine skin shares considerable anatomical and physiological similarities with human skin, including comparable epidermal thickness, collagen structure, and immunological responses. Demonstrating efficacy and safety in this context lays a solid foundation for subsequent human trials and regulatory approval pathways, bridging the gap between bench science and bedside application.

The safety profile of the Smad7 biologic was rigorously evaluated, with no evidence of adverse immune reactions or systemic toxicity noted in treated animals. This finding is paramount given the complexities of modulating growth factor pathways, which are intimately linked to tissue homeostasis and tumorigenesis. The targeted nature of Smad7 overexpression, confined to the wound microenvironment, minimizes risks commonly associated with systemic biologic therapies and underscores the potential for a highly targeted, personalized medicine approach.

Furthermore, the study’s interdisciplinary approach, combining molecular biology, bioengineering, and translational medicine, exemplifies the contemporary trajectory of therapeutic innovation. The integration of precision gene modulation techniques with well-characterized animal models paves the way for next-generation treatments that capitalize on our growing understanding of wound pathophysiology and cellular signaling networks.

Looking ahead, this research opens exciting prospects for expanding Smad7-targeted therapies to other chronic fibrotic conditions beyond diabetic wounds, such as scleroderma, pulmonary fibrosis, and liver cirrhosis, where dysregulated TGF-β signaling plays a pathogenic role. The modular design of the delivery system also allows for adaptability, potentially enabling combinatorial approaches incorporating other regenerative factors or anti-inflammatory molecules.

In summary, the Smad7-based biologic targeting both the epidermis and dermal stroma heralds a transformative capability to enhance diabetic wound healing by precisely reprogramming cellular pathways essential for tissue regeneration. This work not only addresses a pressing clinical need but also exemplifies the convergence of advanced molecular techniques with translational science to create impactful therapies. As diabetic ulcer prevalence escalates globally due to the rising incidence of diabetes mellitus, such innovations provide hope for dramatically improved patient outcomes and reduced healthcare burdens.

Given the complexity and chronic nature of diabetic wounds, therapies that can orchestrate a reset of the wound microenvironment—from a stalled, inflammatory niche to a regenerative milieu—represent the frontier of clinical care. The Smad7 biologic’s ability to simultaneously suppress fibrosis and stimulate reparative activity positions it uniquely among emerging treatments. Its success in preclinical models serves as a compelling invitation to accelerate human trials and develop scalable manufacturing processes, ensuring future accessibility.

The potential to drastically reduce healing times and improve tissue quality could diminish rates of infection, hospitalization, and limb loss, significantly improving quality of life for millions. Furthermore, such biologics may integrate seamlessly into multidisciplinary care regimens, combining surgical, pharmacologic, and bioengineering strategies to optimize therapeutic outcomes.

Ultimately, this milestone illustrates the remarkable power of molecular genetics and targeted therapies to solve some of medicine’s most intractable challenges. Smad7’s modulation of the TGF-β pathway exemplifies how deepening our mechanistic insights can translate into lifesaving innovations. As this research progresses toward the clinic, its promise heralds a new era in regenerative medicine and chronic wound management, illuminating a path forward for patients and physicians alike.

Subject of Research: Diabetic wound healing using Smad7-based biologic targeting epidermis and stroma

Article Title: Smad7-based biologic targeting epidermis and stroma promotes healing of diabetic wounds in mice and pigs

Article References:
Ke, Y., Li, BZ., Li, F. et al. Smad7-based biologic targeting epidermis and stroma promotes healing of diabetic wounds in mice and pigs. Nat Commun (2026). https://doi.org/10.1038/s41467-026-70790-9

Image Credits: AI Generated

Diabetic wounds represent a severe complication arising from impaired glucose metabolism, often culminating in infections, ulcers, and even amputations. Despite advances in wound care, healing in diabetic patients is notoriously delayed, attributed in part to persistent inflammation and dysfunctional cellular responses. The current study sheds light on the epigenetic and immunological mechanisms that disrupt keratinocyte activity, the primary cell type responsible for re-epithelialization during wound repair.

IL-17A, a cytokine historically characterized in autoimmune and inflammatory contexts, has been discovered here to be significantly elevated in the microenvironment of diabetic wounds. This increase in IL-17A levels initiates a cascade of intracellular events within keratinocytes that adversely affect their proliferative and migratory capabilities. Importantly, the study reveals that IL-17A’s deleterious effects are mediated through the upregulation of JMJD3, a histone demethylase known to modulate gene expression by remodeling chromatin structure.

The authors employed an array of in vitro and in vivo experiments to validate this pathway. By analyzing skin biopsies from diabetic patients and corresponding murine models, they demonstrated a stark correlation between high IL-17A concentrations and altered JMJD3 activity in keratinocytes. Furthermore, pharmacological inhibition or genetic knockdown of JMJD3 restored normal keratinocyte function, underscoring the enzyme’s pivotal role in the pathogenesis of non-healing wounds.

At the molecular level, JMJD3 operates by demethylating histone H3 on lysine 27 (H3K27me3), a key epigenetic mark associated with gene repression. The removal of this mark unleashes a transcriptional program that dysregulates genes essential for keratinocyte proliferation and migration. The study meticulously profiles these gene expression changes, illustrating how IL-17A-driven JMJD3 activity disrupts the finely tuned balance of wound healing processes.

What distinguishes this study is its integration of immunology and epigenetics to explain a clinical phenomenon that has long eluded comprehensive explanation. Chronic inflammation, typified by sustained IL-17A signaling, perpetuates an epigenetic landscape unfavorable for tissue regeneration. This intersection of signaling pathways and chromatin modification represents a paradigm shift in our understanding of diabetic wound chronicity.

In practical terms, the identification of JMJD3 as a mediator of IL-17A’s harmful effects provides a promising target for pharmaceutical development. Therapeutic agents that inhibit JMJD3 activity in keratinocytes could potentially reverse the epigenetic blockade and restore normal wound healing trajectories. Considering the limited efficacy of current treatments, such targeted approaches hold substantial promise for improving patient outcomes.

The broader implications extend beyond diabetic wound healing. Since IL-17A and JMJD3 are implicated in various inflammatory disorders, the mechanistic insights gained here might inform strategies for conditions where pathological inflammation and epigenetic dysregulation coexist. The study invites further exploration into how histone demethylases intersect with immune signals in tissue injury and repair.

From a methodological perspective, the study leverages cutting-edge genomic and epigenomic tools. Chromatin immunoprecipitation sequencing (ChIP-seq) allowed precise mapping of histone modification changes in keratinocytes, while RNA sequencing cataloged transcriptional shifts induced by IL-17A and JMJD3 interplay. These high-resolution techniques underpin the robustness and depth of the findings.

Future research prompted by these results might explore the temporal dynamics of IL-17A and JMJD3 expression during different wound healing phases. Understanding when and how these factors peak could guide the timing of therapeutic interventions to maximize efficacy. Additionally, dissecting potential crosstalk with other signaling pathways involved in wound repair may illuminate combinatorial targets.

Clinically, monitoring IL-17A and JMJD3 levels in patients could evolve into a biomarker strategy, predicting wound healing trajectories and personalizing treatment plans. This precision medicine approach would allow clinicians to stratify patients based on molecular profiles, optimizing resource allocation and therapeutic success.

The study also raises intriguing questions regarding the source of IL-17A in diabetic wounds. Immune cells such as Th17 lymphocytes are principal producers; dissecting the recruitment and activation cues for these cells in hyperglycemic tissue environments could reveal upstream targets to curb IL-17A elevation itself.

Overall, the work by Moon and colleagues exemplifies the power of multidisciplinary research to unravel complex pathophysiological mechanisms. The synergy of immunology, epigenetics, dermatology, and molecular biology culminates in a discovery with tangible potential for translational impact. As diabetic wound care continues to pose global health challenges, such mechanistic breakthroughs are critical.

In summation, the identification of IL-17A-induced JMJD3 activation as a driver of keratinocyte dysfunction reshapes our understanding of diabetic wound chronicity. By elucidating the epigenetic underpinnings of impaired healing, this research paves the way for innovative therapies that could revolutionize care for millions suffering from chronic wounds. The integration of inflammatory signaling and chromatin remodeling offers a compelling target landscape for next-generation interventions poised to restore normal skin regeneration.

Subject of Research:
The study focuses on the molecular mechanisms underlying impaired keratinocyte function in diabetic wounds, particularly investigating how the inflammatory cytokine IL-17A affects wound healing through epigenetic modification involving histone demethylase JMJD3.

Article Title:
IL-17A is increased in diabetic wounds and impairs keratinocyte function via histone demethylase JMJD3.

Article References:
Moon, J.Y., Wolf, S.J., Joshi, A.D. et al. IL-17A is increased in diabetic wounds and impairs keratinocyte function via histone demethylase JMJD3. Nat Commun (2025). https://doi.org/10.1038/s41467-025-67456-3

Image Credits:
AI Generated

For decades, diabetic wounds have presented a stubborn clinical challenge, notoriously resistant to conventional treatment and often culminating in severe complications, including infections and amputations. Despite intense research efforts, the precise molecular disruptions responsible for this impaired healing have largely remained elusive. This new investigation delves deeply into the biophysical properties of cellular proteins at wound sites, uncovering that phase separation—a process by which biomolecules spontaneously demix to form distinct membraneless compartments—is critical for coordinating the intricate cascade of cellular behaviors necessary for tissue repair.

Central to this process is Galectin-3, a β-galactoside-binding lectin widely implicated in cell adhesion, immune responses, and tissue remodeling. Under physiological conditions, Galectin-3 interacts intimately with integrin α5β1, a key transmembrane receptor that mediates cell-extracellular matrix adhesion and signaling. The new study reveals that these interactions are not random but are governed by a phase separation mechanism, allowing Galectin-3 and integrin α5β1 to cluster into dynamic assemblies at the wound milieu. These assemblies orchestrate crucial signaling hubs that promote cell migration, proliferation, and extracellular matrix deposition, all essential steps for effective wound closure.

However, in diabetic environments, this delicate equilibrium is perturbed by the pathological accumulation of AGEs. These molecules are the result of non-enzymatic glycation of proteins, lipids, and nucleic acids due to chronic hyperglycemia. AGEs are notorious for eliciting tissue stiffness, oxidative stress, and inflammation. The latest research uncovers a novel injurious role for AGEs: their direct interference with the phase separation of Galectin-3 and integrin α5β1 complexes. By binding to these proteins or altering their local environment, AGEs thwart the formation of functional condensates, leading to impaired cellular adhesion and signaling at wound sites.

The team employed cutting-edge cellular imaging and biophysical assays to visualize and quantify the assembly of Galectin-3 and integrin α5β1 complexes. Using rodent models genetically engineered to mimic the diabetic state, they demonstrated that disrupting the formation of these phase-separated assemblies correlates strongly with slowed wound healing and compromised tissue integrity. Notably, they were able to rescue the impaired healing phenotype by pharmacologically targeting AGE accumulation, thereby restoring proper phase separation dynamics and downstream signaling.

This compelling evidence firmly establishes phase separation as a previously unrecognized regulatory layer in diabetic wound pathology. The study’s implications extend beyond wound healing: it paints a broader picture of how post-translational modifications and metabolic byproducts can disrupt biophysical protein interactions, thereby modulating cellular function in disease contexts. The concept of phase separation has revolutionized cell biology over the past decade, but its connection to chronic metabolic disorders is only beginning to be explored.

Furthermore, these insights provide a molecular rationale for longstanding clinical observations linking poor glycemic control with delayed wound closure. By pinpointing the molecular culprit—AGE interference with Galectin-3-integrin condensates—the research opens potential therapeutic avenues aimed at restoring or mimicking these phase-separated compartments. For instance, small molecules or peptides designed to stabilize Galectin-3 and integrin interactions or inhibitors that prevent AGE formation could revolutionize treatment modalities for diabetic ulcers and other chronic wounds.

The study also highlights the importance of the extracellular matrix context in modulating phase separation events. Integrin α5β1, a primary receptor for fibronectin, anchors cells to their surrounding matrix, allowing them to sense and respond to biochemical and mechanical cues. The disruption caused by AGEs likely alters not only protein-protein interactions within cells but also the cell-matrix adhesion landscape, compounding the challenges cells face during tissue repair. Future investigations may unravel the feedback loops between extracellular modifications and intracellular condensate dynamics.

Importantly, the research underscores the necessity of interdisciplinary approaches combining biophysics, molecular biology, and disease modeling to unravel complex pathological mechanisms. By integrating live-cell imaging, protein chemistry, and diabetic rodent models, the authors constructed a comprehensive framework linking molecular condensates to tissue-level outcomes. Such integrative strategies are crucial to translate fundamental biophysical phenomena into actionable biomedical insights.

Intriguingly, Galectin-3 has been implicated in numerous pathological conditions beyond diabetes, including cancer metastasis and fibrosis. Its capacity to undergo phase separation with integrins may represent a generalizable mechanism for organizing cell-matrix interactions across diverse biological processes. The specific vulnerability of these condensates to AGE modification may thus have relevance in other chronic diseases characterized by oxidative stress and protein glycation.

The authors also addressed the temporal dynamics of these phase-separated condensates during the wound healing process. Their observations indicate that the formation and dissolution of Galectin-3-integrin ensembles are tightly regulated, corresponding to distinct phases of cellular migration and extracellular matrix remodeling. Disruption by AGEs causes prolonged or incomplete condensate formation, which may stall cellular progression through the healing stages, resulting in chronic wound states typically observed in diabetic patients.

At the cellular signaling level, the disassembly of Galectin-3-integrin condensates was shown to impair downstream pathways involving focal adhesion kinase (FAK) and extracellular signal-regulated kinase (ERK), both crucial for cell motility and survival. This mechanistic insight provides tangible targets for intervention, as pharmacological modulation of these signaling axes might compensate for defective phase separation and enhance wound resolution.

Another notable breakthrough is the potential reversibility of the impaired condensate formation. The research demonstrated that treatment with AGE inhibitors not only halts further damage but partially restores the ability of Galectin-3 and integrin α5β1 to phase separate. This finding offers hope for therapeutic windows during which intervention can rescue or improve healing outcomes, especially if detected early in the diabetic wound progression.

Looking forward, this research invites further exploration into other glycated proteins that might interfere with phase separation-dependent cellular functions. The concept that metabolic dysfunction exerts wide-reaching effects through the alteration of biomolecular condensates could redefine disease paradigms and inspire innovative drug discovery programs targeting condensate biophysics.

In conclusion, the elucidation of Galectin-3-integrin α5β1 phase separation as a critical regulator of diabetic wound healing, and its disruption by AGEs, represents a major advance in the field of regenerative medicine and metabolic disease research. By linking a biophysical property of proteins to clinical pathology, the study bridges fundamental biology with translational potential. This novel mechanistic insight not only deepens our understanding of diabetic complications but also lights a path toward more effective treatments for the millions suffering from impaired wound healing worldwide.

Subject of Research: Diabetic wound healing impairment due to disruption of protein phase separation by advanced glycation end-products.

Article Title: Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents.

Article References:
Zhang, Z., Zhao, Z., Huang, X. et al. Galectin-3-integrin α5β1 phase separation disrupted by advanced glycation end-products impairs diabetic wound healing in rodents. Nat Commun 16, 7287 (2025). https://doi.org/10.1038/s41467-025-62320-w

Image Credits: AI Generated